Novel Coronavirus disease 2019 (COVID-19) represents an emergent global health burden that has challenged the health systems worldwide. Since its sudden upsurge in 2019, many COVID-19 patients have exhibited neurological symptoms and complications. Till now, there is no known effective established drug against the highly contagious COVID-19 infection despite the frightening associated mortality rate. This article aims to present the mechanism of action of coronavirus-2 (SARS-CoV-2), the clinical neurological manifestations displayed by COVID-19 patients, and present polyphenols with neuroprotective ability that can offer beneficial effects against COVID-19-mediated neuropathology. Reports from COVID-19 clinical studies, case reports, and other related literature were evaluated for this review. Neurological complications of COVID-19 include anosmia, acute cerebrovascular disease, acute disseminated post-infectious encephalomyelitis, encephalitis, etc. Also, SARS-CoV-2 sould be a neurotropic vіruѕ due to its iѕolatіon from serebroѕrіnal fluіd. Multіrle neurologіsal damages displayed by COVID-19 patients might be due to hyperinflammation associated with SARS-CoV-2 infections. Resveratrol, kolaviron, quercetin and apigenin are polyphenols with proven anti-inflammatory and therapeutic properties that can extenuate the adverse effects of COVID-19. These polyphenols have been documented to suppress c-Jun N-terminal kinase (JNK), phosphoinositide-3-kinase (PI3-K), extrasellularѕіgnal-regulated kinase (ERK), nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-kB) and mіtogen-astіvated protein kіnaѕe (MAPK) pathways which are essential in the pathogenesis of COVID-19. They also showed significant inhibitory activities against SARS-CoV-2 proteins. Taken together, these polyphenols may offer neuroprotective benefits against COVID-19 mediated neuropathology via modulation of the pathogenic pathways.
References
1.
2020;
2.
N.C.D.C. Coronavirus COVID-19.
3.
Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708–20.
4.
Organization WH. Q&A on coronaviruses (COVID-19);2020.
5.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507–13.
6.
Ahmed MU, Hanif M, Ali MJ, Haider MA, Kherani D, Memon GM, et al. Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review. Frontiers in Neurology. 11.
7.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020;77(6):683.
8.
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chemical Neuroscience. 2020;11(7):995–8.
9.
Wong SH, Lui RN, Sung JJ. Covid‐19 and the digestive system. Journal of Gastroenterology and Hepatology. 2020;35(5):744–8.
10.
Swanson PA, McGavern DB. Viral diseases of the central nervous system. Current Opinion in Virology. 2015;11:44–54.
11.
Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients. Journal of Medical Virology. 2020;92(6):552–5.
12.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. The Lancet. 2014;383(9927):1503–16.
13.
Henter JI. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–73.
14.
Seguin A, Galicier L, Boutboul D, Lemiale V, Azoulay E. Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis. Chest. 2016;149(5):1294–301.
15.
Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory Virus Infections. Frontiers in Cellular Neuroscience. 12.
16.
van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, et al. Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans. mBio. 2012;3(6).
17.
Phan T. Novel coronavirus: From discovery to clinical diagnostics. Infection, Genetics and Evolution. 2020;79:104211.
18.
Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2. Journal of Medical Virology. 2020;92(6):595–601.
19.
Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S, et al. Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response. Journal of Virology. 2011;85(9):4122–34.
20.
Bertram S, Glowacka I, Müller MA, Lavender H, Gnirss K, Nehlmeier I, et al. Cleavage and Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by Human Airway Trypsin-Like Protease. Journal of Virology. 2011;85(24):13363–72.
21.
Chan JFW, To KKW, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends in Microbiology. 2013;21(10):544–55.
22.
Siu K, Yuen K, Castano‐Rodriguez C, Ye Z, Yeung M, Fung S, et al. Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3‐dependent ubiquitination of ASC. The FASEB Journal. 2019;33(8):8865–77.
23.
Nieto-Torres JL, Verdiá-Báguena C, Jimenez-Guardeño JM, Regla-Nava JA, Castaño-Rodriguez C, Fernandez-Delgado R, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology. 2015;485:330–9.
24.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506.
25.
Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host & Microbe. 2020;27(3):325–8.
26.
Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020;10(5):766–88.
27.
Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 12(2):244.
28.
Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(5):1275–80.
29.
Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130–7.
30.
Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2.
31.
Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cellular & Molecular Immunology. 2020;17(6):613–20.
32.
Li Y, Yao J, Han C, Yang J, Chaudhry M, Wang S, et al. Quercetin, Inflammation and Immunity. Nutrients. 8(3):167.
33.
Guo Y, Bruno RS. Endogenous and exogenous mediators of quercetin bioavailability. The Journal of Nutritional Biochemistry. 2015;26(3):201–10.
34.
Nair MPN, Kandaswami C, Mahajan S, Chadha KC, Chawda R, Nair H, et al. The flavonoid, quercetin, differentially regulates Th-1 (IFNγ) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2002;1593(1):29–36.
35.
Robaszkiewicz A, Balcerczyk A, Bartosz G. Antioxidative and prooxidative effects of quercetin on A549 cells. Cell Biology International. 2007;31(10):1245–50.
36.
Uchide N, Toyoda H. Antioxidant Therapy as a Potential Approach to Severe Influenza-Associated Complications. Molecules. 16(3):2032–52.
37.
Quercetin KGS. Monograph. Altern Med Rev. 2011;16: (2:172–94.
38.
Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochemical Pharmacology. 2012;83(1):6–15.
39.
Boots AW, Haenen GRMM, Bast A. Health effects of quercetin: From antioxidant to nutraceutical. European Journal of Pharmacology. 2008;585(2–3):325–37.
40.
Spedding G, Ratty A, Middleton E. Inhibition of reverse transcriptases by flavonoids. Antiviral Research. 1989;12(2):99–110.
41.
Bachmetov L, Gal‐Tanamy M, Shapira A, Vorobeychik M, Giterman‐Galam T, Sathiyamoorthy P, et al. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. Journal of Viral Hepatitis. 2012;19(2).
42.
Shinozuka K, Kikuchi Y, Nishino C, Mori A, Tawata S. Inhibitory effect of flavonoids on DNA-dependent DNA and RNA polymerases. Experientia. 1988;44(10):882–5.
43.
Cushnie TPT, Lamb AJ. Antimicrobial activity of flavonoids. International Journal of Antimicrobial Agents. 2005;26(5):343–56.
44.
Debiaggi M, Tateo F, Pagani L. Effects of propolis flavonoids on virus infectivity and replication. Microbiologica. 1990;13:207–13.
45.
Liu S, Wu S, Jiang S. HIV Entry Inhibitors Targeting gp41: From Polypeptides to Small-Molecule Compounds. Current Pharmaceutical Design. 2007;13(2):143–62.
46.
Yang J, Li M, Shen X, Liu S. Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin. Viruses. 5(1):352–73.
47.
Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Research. 2014;194:200–10.
48.
Wu W, Li R, Li X, He J, Jiang S, Liu S, et al. Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry. Viruses. 8(1):6.
49.
Ono K, Nakane H. Mechanisms of Inhibition of Various Cellular DNA and RNA Polymerases by Several Flavonoids. The Journal of Biochemistry. 1990;108(4):609–13.
50.
ONO K, NAKANE H, FUKUSHIMA M, CHERMANN J, BARRÉ‐SINOUSSI F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. European Journal of Biochemistry. 1990;190(3):469–76.
51.
Chiang LC. In vitro antiviral activities of Caesalpinia pulcherrima and its related flavonoids. Journal of Antimicrobial Chemotherapy. 52(2):194–8.
52.
Li BW, Zhang FH, Serrao E, Chen H, Sanchez TW, Yang LM, et al. Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75. Bioorganic & Medicinal Chemistry. 2014;22(12):3146–58.
53.
Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G, et al. Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells. Journal of Virology. 2004;78(20):11334–9.
54.
Chen L, Li J, Luo C, Liu H, Xu W, Chen G, et al. Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal salient pharmacophore features. Bioorganic & Medicinal Chemistry. 2006;14(24):8295–306.
55.
Rane JS, Chatterjee A, Kumar A, Ray S. Targeting SARS-CoV-2 Spike Protein of COVID-19 with Naturally Occurring Phytochemicals: An in Silco Study for Drug Development.
56.
Jeandet P, Douillet-Breuil AC, Bessis R, Debord S, Sbaghi M, Adrian M. Phytoalexins from the Vitaceae: Biosynthesis, Phytoalexin Gene Expression in Transgenic Plants, Antifungal Activity, and Metabolism. Journal of Agricultural and Food Chemistry. 2002;50(10):2731–41.
57.
De Santi C, Pietrabissa A, Mosca F, Pacifici GM. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica. 2000;30(11):1047–54.
58.
De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica. 2000;30(9):857–66.
59.
Ribeiro de Lima MT, Waffo-Téguo P, Teissedre PL, Pujolas A, Vercauteren J, Cabanis JC, et al. Determination of Stilbenes (trans-Astringin,cis- andtrans-Piceid, andcis- andtrans-Resveratrol) in Portuguese Wines. Journal of Agricultural and Food Chemistry. 1999;47(7):2666–70.
60.
Berzas Nevado JJ, Contento Salcedo AM, Castañeda Peñalvo G. Simultaneous determination of cis- and trans-resveratrol in wines by capillary zone electrophoresis. The Analyst. 1999;124(1):61–6.
61.
Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the “French paradox”? European Journal of Endocrinology. 1998;138(6):619–20.
62.
Hengst JA, Yun JK. Sphingosine kinase: a key to solving the ‘French Paradox’? British Journal of Pharmacology. 2012;166(5):1603–4.
63.
Ferrières J. The French paradox: lessons for other countries. Heart. 2004;90(1):107–11.
64.
Constant J. Alcohol, ischemic heart disease, and the French paradox. Coronary Artery Disease. 1997;8(10):645–50.
65.
Wang Z, Zou J, K C. Dealcoholized red wine containing known amounts ofresveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med. 2005;16:533–40.
66.
Szmitko PE, Verma S. Red Wine and Your Heart. Circulation. 2005;111(2).
67.
Berardi V, Ricci F, Castelli M, Galati G, Risuleo G. Resveratrol exhibits a strong cytotoxic activity in cultured cells and has an antiviral action against polyomavirus: potential clinical use. Journal of Experimental & Clinical Cancer Research. 2009;28(1).
68.
Clouser CL, Chauhan J, Bess MA, Oploo JL van, Zhou D, Dimick-Gray S, et al. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorganic & Medicinal Chemistry Letters. 2012;22(21):6642–6.
69.
Nicolini G, Rigolio R, Miloso M, Bertelli AAE, Tredici G. Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neuroscience Letters. 2001;302(1):41–4.
70.
Baarine M, Thandapilly SJ, Louis XL, Mazué F, Yu L, Delmas D, et al. Pro-apoptotic versus anti-apoptotic properties of dietary resveratrol on tumoral and normal cardiac cells. Genes & Nutrition. 2011;6(2):161–9.
71.
Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutrition Reviews. 66(8):445–54.
72.
Chen G, Shan W, Wu Y, Ren L, Dong J, Ji Z. Synthesis and Anti-inflammatory Activity of Resveratrol Analogs. Chemical and Pharmaceutical Bulletin. 2005;53(12):1587–90.
73.
Effect of Resveratrol on Oxidative and Inflammatory Stress in Liver and Spleen of Streptozotocin-Induced Type 1 Diabetic Rats. The Chinese Journal of Physiology. 55(3).
74.
Dao TMA, Waget A, Klopp P, Serino M, Vachoux C, Pechere L, et al. Resveratrol Increases Glucose Induced GLP-1 Secretion in Mice: A Mechanism which Contributes to the Glycemic Control. PLoS ONE. 6(6):e20700.
75.
Spanier G, Xu H, Xia N. Resveratrol reduces endothelialoxidative stress by modulating the gene expression of superoxidedismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4. J Physiol Pharmacol. 2009;60:111–6.
76.
Vella F, Ferry G, Delagrange P, Boutin JA. NRH:quinone reductase 2: An enzyme of surprises and mysteries. Biochemical Pharmacology. 2005;71(1–2):1–12.
77.
Benoit CE, Bastianetto S, Brouillette J, Tse Y, Boutin JA, Delagrange P, et al. Loss of Quinone Reductase 2 Function Selectively Facilitates Learning Behaviors. The Journal of Neuroscience. 2010;30(38):12690–700.
78.
Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: Role of resveratrol in microglial activation. European Journal of Pharmacology. 2010;636(1–3):1–7.
79.
Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochemical Society Transactions. 2007;35(5):1127–32.
80.
Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson’s disease. Trends in Pharmacological Sciences. 2003;24(8):395–401.
81.
Ransohoff RM, Perry VH. Microglial Physiology: Unique Stimuli, Specialized Responses. Annual Review of Immunology. 2009;27(1):119–45.
82.
Candelario-Jalil E, de Oliveira ACP, Gräf S, Bhatia HS, Hüll M, Muñoz E, et al. Resveratrol potently reduces prostaglandin E2production and free radical formation in lipopolysaccharide-activated primary rat microglia. Journal of Neuroinflammation. 2007;4(1).
83.
Lorenz P, Roychowdhury S, Engelmann M, Wolf G, Horn TFW. Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: effect on nitrosative and oxidative stress derived from microglial cells. Nitric Oxide. 2003;9(2):64–76.
84.
Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T, et al. Resveratrol inhibits nitric oxide and TNF-α production by lipopolysaccharide-activated microglia. International Immunopharmacology. 2005;5(1):185–93.
85.
Bureau G, Longpré F, Martinoli M ‐G. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. Journal of Neuroscience Research. 2008;86(2):403–10.
86.
Shin JA, Lee H, Lim YK, Koh Y, Choi JH, Park EM. Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. Journal of Neuroimmunology. 2010;227(1–2):93–100.
87.
Oladele JO, Ajayi EI, Oyeleke OM, Oladele OT, Olowookere BD, Adeniyi BM, et al. A systematic review on COVID-19 pandemic with special emphasis on curative potentials of Nigeria based medicinal plants. Heliyon. 2020;6(9):e04897.
88.
Dewick PM. Chimica, Biosintesi e Bioattivitàdelle Sostanze Naturali; Piccin. 2001;
89.
Campbell EL, Chebib M, Johnston GAR. The dietary flavonoids apigenin and (−)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABAA receptors. Biochemical Pharmacology. 2004;68(8):1631–8.
90.
Jäger AK, Krydsfeldt K, Rasmussen HB. Bioassay‐guided isolation of apigenin with GABA‐benzodiazepine activity from Tanacetum parthenium. Phytotherapy Research. 2009;23(11):1642–4.
91.
Sloley BD, Urichuk LJ, Morley P, Durkin J, Shan JJ, Pang PKT, et al. Identification of Kaempferol as a Monoamine Oxidase Inhibitor and Potential Neuroprotectant in Extracts of Ginkgo Biloba Leaves. Journal of Pharmacy and Pharmacology. 2000;52(4):451–9.
92.
Zhao L, Wang JL, Liu R, Li XX, Li JF, Zhang L. Neuroprotective, Anti-Amyloidogenic and Neurotrophic Effects of Apigenin in an Alzheimer’s Disease Mouse Model. Molecules. 18(8):9949–65.
93.
Nabavi SF, Khan H, D’onofrio G, Šamec D, Shirooie S, Dehpour AR, et al. Apigenin as neuroprotective agent: Of mice and men. Pharmacological Research. 2018;128:359–65.
94.
Rezai-Zadeh K, Ehrhart J, Bai Y, Sanberg PR, Bickford P, Tan J, et al. Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. Journal of Neuroinflammation. 2008;5(1).
95.
Nicholas C, Batra S, Vargo MA, Voss OH, Gavrilin MA, Wewers MD, et al. Apigenin Blocks Lipopolysaccharide-Induced Lethality In Vivo and Proinflammatory Cytokines Expression by Inactivating NF-κB through the Suppression of p65 Phosphorylation. The Journal of Immunology. 2007;179(10):7121–7.
96.
Myhrstad MCW, Carlsen H, Nordström O, Blomhoff R, Moskaug JØ. Flavonoids increase the intracellular glutathione level by transactivation of the γ-glutamylcysteine synthetase catalytical subunit promoter. Free Radical Biology and Medicine. 2002;32(5):386–93.
97.
Paredes‐Gonzalez X, Fuentes F, Jeffery S, Saw CL, Shu L, Su Z, et al. Induction of NRF2‐mediated gene expression by dietary phytochemical flavones apigenin and luteolin. Biopharmaceutics & Drug Disposition. 2015;36(7):440–51.
98.
Huang CS, Lii CK, Lin AH, Yeh YW, Yao HT, Li CC, et al. Protection by chrysin, apigenin, and luteolin against oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase 1 and glutamate cysteine ligase in rat primary hepatocytes. Archives of Toxicology. 2013;87(1):167–78.
99.
Peng Q, Deng Z, Pan H, Gu L, Liu O, Tang Z. Mitogen-activated protein kinase signaling pathway in oral cancer (Review). Oncology Letters.
100.
Oladele JO, Oyeleke OM, Oladele OT, Olowookere BD, Oso BJ, Oladiji AT. Kolaviron (Kolaflavanone), apigenin, fisetin as potential Coronavirus inhibitors: In silico investigation.
101.
Oladele JO, Oladele OT, Ademiluyi AO, Oyeleke OM, Awosanya OO, Oyewole OI. Chaya (Jatropha tanjorensis) leafs protect against sodium benzoate mediated renal dysfunction and hepatic damage in rats. Clinical Phytoscience. 2020;6(1).
102.
Oladele JO, Oyeleke OM, Oladele OT, Babatope OD, Awosanya OO. Nitrobenzene-induced hormonal disruption, alteration of steroidogenic pathway, and oxidative damage in rat: protective effects of Vernonia amygdalina. Clinical Phytoscience. 2020;6(1).
103.
Oladele JO, Oyeleke OM, Awosanya OO, Olowookere BD, Oladele OT. Fluted Pumpkin (Telfairia occidentalis) protects against phenyl hydrazine-induced anaemia and associated toxicities in rats. Advances in Traditional Medicine. 2021;21(4):739–45.
104.
Oladele JO, Oyeleke OM, Oladele OT, Olaniyan M. Neuroprotective mechanism of Vernonia amygdalina in a rat model of neurodegenerative diseases. Toxicology Reports. 2020;7:1223–32.
105.
Olaleye Oladele J. Hepatoprotective Effect of Aqueous Extract of <i>Telfairia occidentalis</i> on Cadmium Chloride-Induced Oxidative Stress and Hepatotoxicity in Rats. Journal of Drug Design and Medicinal Chemistry. 2017;3(3):32.
106.
Oyewole OI, Oladele JO, Oladele OT. Methanolic leaf extract of <i>Ficus exasperata</i> attenuates Arsenate–mediated hepatic and renal oxidative stress in rats. Research Journal of Health Sciences. 5(2):115.
107.
Iwu MM. Antihepatoxic constituents ofGarcinia kola seeds. Experientia. 1985;41(5):699–700.
108.
Taiwo O, Xu HX, Lee SF. Antibacterial activities of extracts from Nigerian chewing sticks. Phytotherapy Research. 1999;13(8):675–9.
109.
Farombi EO, Tahnteng JG, Agboola AO, Nwankwo JO, Emerole GO. Chemoprevention of 2-acetylaminofluorene-induced hepatotoxicity and lipid peroxidation in rats by kolaviron—A Garcinia kola seed extract. Food and Chemical Toxicology. 2000;38(6):535–41.
110.
Farombi EO, Adepoju BF, Ola-Davies OE, Emerole GO. Chemoprevention of aflatoxin B1-induced genotoxicity and hepatic oxidative damage in rats by kolaviron, a natural biflavonoid of Garcinia kola seeds. European Journal of Cancer Prevention. 2005;14(3):207–14.
111.
Farombi EO, Shrotriya S, Surh YJ. Kolaviron inhibits dimethyl nitrosamine-induced liver injury by suppressing COX-2 and iNOS expression via NF-κB and AP-1. Life Sciences. 2009;84(5–6):149–55.
112.
Abarikwu SO, Farombi EO, Kashyap MP, Pant AB. Kolaviron protects apoptotic cell death in PC12 cells exposed to Atrazine. Free Radical Research. 2011;45(9):1061–73.
113.
Abarikwu SO, Farombi EO, Pant AB. Biflavanone-kolaviron protects human dopaminergic SH-SY5Y cells against atrazine induced toxic insult. Toxicology in Vitro. 2011;25(4):848–58.
114.
Igado OO, Olopade JO, Adesida A, Aina OO, Farombi EO. Morphological and biochemical investigation into the possible neuroprotective effects of kolaviron (Garciniakola bioflavonoid) on the brains of rats exposed to vanadium. Drug and Chemical Toxicology. 2012;35(4):371–80.
115.
Onasanwo SA, Velagapudi R, El-Bakoush A, Olajide OA. Inhibition of neuroinflammation in BV2 microglia by the biflavonoid kolaviron is dependent on the Nrf2/ARE antioxidant protective mechanism. Molecular and Cellular Biochemistry. 2016;414(1–2):23–36.
116.
Olajide OJ, Asogwa NT, Moses BO, Oyegbola CB. Multidirectional inhibition of cortico-hippocampal neurodegeneration by kolaviron treatment in rats. Metabolic Brain Disease. 2017;32(4):1147–61.
117.
Omotoso GO, Ukwubile II, Arietarhire L, Sulaimon F, Gbadamosi IT. Kolaviron protects the brain in cuprizone-induced model of experimental multiple sclerosis via enhancement of intrinsic antioxidant mechanisms: Possible therapeutic applications? Pathophysiology. 2018;25(4):299–306.
118.
Farombi EO, Awogbindin IO, Farombi TH, Oladele JO, Izomoh ER, Aladelokun OB, et al. Neuroprotective role of kolaviron in striatal redo-inflammation associated with rotenone model of Parkinson’s disease. NeuroToxicology. 2019;73:132–41.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
